

Daniel Matthias Aebersold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6937904/publications.pdf>

Version: 2024-02-01

176
papers

4,519
citations

117453

34
h-index

133063

59
g-index

187
all docs

187
docs citations

187
times ranked

6692
citing authors

#	ARTICLE	IF	CITATIONS
1	Toward Data-Driven Radiation Oncology Using Standardized Terminology as a Starting Point: Cross-sectional Study. JMIR Formative Research, 2022, 6, e27550.	0.7	0
2	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91.	0.4	5
3	Response assessment after stereotactic body radiation therapy for spine and non-spine bone metastases: results from a single institutional study. Radiation Oncology, 2022, 17, 37.	1.2	4
4	A hybrid column generation and simulated annealing algorithm for direct aperture optimization. Physics in Medicine and Biology, 2022, 67, 075003.	1.6	5
5	Development of a Monte Carlo based robustness calculation and evaluation tool. Medical Physics, 2022, 49, 4780-4793.	1.6	2
6	Feasibility of postoperative spine stereotactic body radiation therapy in proximity of carbon and titanium hybrid implants using a robotic radiotherapy device. Radiation Oncology, 2022, 17, 94.	1.2	3
7	A new mouse model of radiation-induced liver disease reveals mitochondrial dysfunction as an underlying fibrotic stimulus. JHEP Reports, 2022, 4, 100508.	2.6	7
8	Organ-at-risk sparing with dynamic trajectory radiotherapy for head and neck cancer: comparison with volumetric arc therapy on a publicly available library of cases. Radiation Oncology, 2022, 17, .	1.2	1
9	Changes of Corneal Biomechanical Properties upon Exclusive Ytt-/Sr-90 Irradiation of Pterygium. Sensors, 2021, 21, 975.	2.1	1
10	Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial.. Journal of Clinical Oncology, 2021, 39, 194-194.	0.8	10
11	Vestibular dose correlates with dizziness after radiosurgery for the treatment of vestibular schwannoma. Radiation Oncology, 2021, 16, 61.	1.2	6
12	Abstract PO-026: DNA damage response and repair characterization in CHK2-deficient cancers. , 2021, , .		0
13	Abstract PO-039: Radiation therapy enhances anti-tumor activity of a MET CAR T-based immunotherapy approach for glioblastoma multiforme. , 2021, , .		0
14	Radiotherapy in nodal oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 575-580.	1.0	11
15	Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury. Cell Death and Disease, 2021, 12, 366.	2.7	8
16	Single early palliative care intervention added to usual oncology care for patients with advanced cancer: A randomized controlled trial (SENS Trial). Palliative Medicine, 2021, 35, 1108-1117.	1.3	12
17	The prognostic impact of daytime and seasonality of radiotherapy on head and neck cancer. Radiotherapy and Oncology, 2021, 158, 293-299.	0.3	4
18	Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).. Journal of Clinical Oncology, 2021, 39, 5010-5010.	0.8	3

#	ARTICLE	IF	CITATIONS
19	The impact of delivery daytime and seasonality of radiotherapy for head and neck cancer on toxicity burden. <i>Radiotherapy and Oncology</i> , 2021, 158, 162-166.	0.3	9
20	Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 993-1000.	1.0	3
21	Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. <i>European Urology</i> , 2021, 80, 306-315.	0.9	64
22	The predictive value of segmentation metrics on dosimetry in organs at risk of the brain. <i>Medical Image Analysis</i> , 2021, 73, 102161.	7.0	11
23	Impact of pretreatment second look 18FDG-PET/CT on stage and treatment changes in head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 31, 8-13.	0.9	2
24	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 109-116.	1.0	14
25	Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 614-626.	1.9	10
26	In Regard to Qi et Al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 224-225.	0.4	0
27	Unplanned hospitalizations in patients with locoregionally advanced head and neck cancer treated with (chemo)radiotherapy with and without prophylactic percutaneous endoscopic gastrostomy. <i>Radiation Oncology</i> , 2020, 15, 281.	1.2	9
28	Fully automated brain resection cavity delineation for radiation target volume definition in glioblastoma patients using deep learning. <i>Radiation Oncology</i> , 2020, 15, 100.	1.2	37
29	A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives. <i>Radiotherapy and Oncology</i> , 2020, 150, 1-3.	0.3	26
30	Impact of Early Prophylactic Cranial Irradiation With Hippocampal Avoidance on Neurocognitive Function in Patients With Limited Disease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK Tj ETQq0 0 0 rBT /Overlock 10 Tf		
31	DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions. , 2020, 215, 107617.		27
32	MET targeting: time for a rematch. <i>Oncogene</i> , 2020, 39, 2845-2862.	2.6	40
33	Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. <i>Molecular Oncology</i> , 2020, 14, 1185-1206.	2.1	7
34	Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 589-597.	1.0	10
35	Treatment compliance and early toxicity in SAKK 01/10: Single-dose carboplatin and involved-node radiotherapy for treatment of stage IIA/B seminoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 405-405.	0.8	6
36	Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. <i>Radiotherapy and Oncology</i> , 2019, 138, 121-125.	0.3	9

#	ARTICLE	IF	CITATIONS
37	ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data. BMC Bioinformatics, 2019, 20, 563.	1.2	7
38	Abiraterone in "High" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. European Urology, 2019, 76, 719-728.	0.9	142
39	Adaptive step size algorithm to increase efficiency of proton macro Monte Carlo dose calculation. Radiation Oncology, 2019, 14, 165.	1.2	4
40	Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer" A Multicenter Study. Frontiers in Oncology, 2019, 9, 932.	1.3	7
41	Skin surface markers for stereotactic body radiation therapy of sternal metastasis. Reports of Practical Oncology and Radiotherapy, 2019, 24, 322-324.	0.3	0
42	Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models. FEBS Journal, 2019, 286, 2692-2710.	2.2	2
43	Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy. Frontiers in Oncology, 2019, 9, 12.	1.3	17
44	Dose analysis of InCise 2 multi leaf collimator and IRIS-based stereotactic radiotherapy plans for brain and liver tumors. Biomedical Physics and Engineering Express, 2019, 5, 035007.	0.6	2
45	Whole-ventricular irradiation for intracranial germ cell tumors: Dosimetric comparison of pencil beam scanned protons, intensity-modulated radiotherapy and volumetric-modulated arc therapy. Clinical and Translational Radiation Oncology, 2019, 15, 53-61.	0.9	14
46	Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases. Radiation Oncology, 2019, 14, 45.	1.2	5
47	Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. Cancer Letters, 2019, 443, 189-202.	3.2	18
48	Comparison of contemporary staging systems for oropharynx cancer in a surgically treated multi-institutional cohort. Head and Neck, 2019, 41, 1395-1402.	0.9	3
49	Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients. Strahlentherapie Und Onkologie, 2019, 195, 468-474.	1.0	7
50	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 619-626.	1.0	26
51	Independent Monte-Carlo dose calculation for MLC based CyberKnife radiotherapy. Physics in Medicine and Biology, 2018, 63, 015015.	1.6	6
52	Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1 α levels under hypoxia. Oncogene, 2018, 37, 4181-4196.	2.6	19
53	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiotherapy and Oncology, 2018, 126, 257-262.	0.3	19
54	GERM-09. WHOLE VENTRICULAR IRRADIATION FOR INTRACRANIAL GERM CELL TUMORS: DOSIMETRIC COMPARISON OF PENCIL BEAM SCANNED PROTONS VS. IMRT. Neuro-Oncology, 2018, 20, i85-i85.	0.6	0

#	ARTICLE	IF	CITATIONS
55	A dosimetric evaluation of different levels of energy and intensity modulation for inversely planned multi-field MERT. Biomedical Physics and Engineering Express, 2018, 4, 045003.	0.6	1
56	Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. Radiation Oncology, 2018, 13, 216.	1.2	46
57	Part 1: Optimization and evaluation of dynamic trajectory radiotherapy. Medical Physics, 2018, 45, 4201-4212.	1.6	26
58	The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. Molecular Cancer, 2018, 17, 27.	7.9	36
59	A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiotherapy and Oncology, 2018, 129, 257-263.	0.3	10
60	Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease. Molecular Cancer Research, 2018, 16, 1912-1926.	1.5	22
61	Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. Journal of Translational Medicine, 2018, 16, 223.	1.8	60
62	SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy.. Journal of Clinical Oncology, 2018, 36, TPS157-TPS157.	0.8	1
63	In Regard to Pisansky etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 438-439.	0.4	1
64	T1â€2 glottic cancer treated with radiotherapy and/or surgery. Strahlentherapie Und Onkologie, 2017, 193, 995-1004.	1.0	23
65	Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 982-995.	0.4	56
66	Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the <scp>SAKK</scp> 09/10 randomized trial on prostate cancer. BJU International, 2017, 120, E45-E51.	1.3	13
67	PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Molecular Cancer, 2017, 16, 93.	7.9	18
68	Current status and perspectives of interventional clinical trials for glioblastoma â€ analysis of ClinicalTrials.gov. Radiation Oncology, 2017, 12, 1.	1.2	87
69	External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. Radiation Oncology, 2017, 12, 12.	1.2	8
70	Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study. Radiation Oncology, 2017, 12, 97.	1.2	18
71	Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg?. Radiation Oncology, 2017, 12, 102.	1.2	3
72	Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer. Biochemical Pharmacology, 2017, 126, 1-12.	2.0	13

#	ARTICLE	IF	CITATIONS
73	Hypofractionated radiotherapy for localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 1-12.	1.0	40
74	Biomechanical Modeling of Pterygium Radiation Surgery: A Retrospective Case Study. <i>Sensors</i> , 2017, 17, 1200.	2.1	3
75	Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer – a retrospective study. <i>Radiation Oncology</i> , 2017, 12, 202.	1.2	8
76	Altered regulation of ERK1b by MEK1 and PTP-SL and modified Elk1 phosphorylation by ERK1b are caused by abrogation of the regulatory C-terminal sequence of ERKs.. <i>Journal of Biological Chemistry</i> , 2017, 292, 8852.	1.6	1
77	Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1490-1491.	0.8	1
78	A mathematical approach to human pterygium shape. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1343-1349.	0.9	2
79	Role of Dose Intensification for Salvage Radiation Therapy after Radical Prostatectomy. <i>Frontiers in Oncology</i> , 2016, 6, 48.	1.3	3
80	Reply to C. Cozzarini et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1705-1706.	0.8	0
81	Assessing dose rate distributions in VMAT plans. <i>Physics in Medicine and Biology</i> , 2016, 61, 3208-3221.	1.6	4
82	Bladder-Preserving Combined-Modality Therapy: What Is Coming Next? A Critical Analysis of Phase 2-3 Trials of the ClinicalTrials.gov Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E283.	0.4	0
83	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 552-560.	1.0	13
84	Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5322-5336.	3.2	27
85	Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. <i>Radiation Oncology</i> , 2016, 11, 48.	1.2	12
86	Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes – A systematic review. <i>Radiotherapy and Oncology</i> , 2016, 119, 185-193.	0.3	21
87	Radiation Therapy Versus Radical Prostatectomy: A Never-ending Discussion. <i>European Urology</i> , 2016, 70, 31-32.	0.9	4
88	Outcomes in Advanced Head and Neck Cancer Treated with Up-front Neck Dissection prior to (Chemo)Radiotherapy. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 154, 300-308.	1.1	14
89	Implications of intraglandular lymph node metastases in primary carcinomas of the parotid gland. <i>Laryngoscope</i> , 2015, 125, 2099-2106.	1.1	24
90	Profiling Invasiveness in Head and Neck Cancer: Recent Contributions of Genomic and Transcriptomic Approaches. <i>Cancers</i> , 2015, 7, 585-597.	1.7	8

#	ARTICLE	IF	CITATIONS
91	Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer. Radiation Oncology, 2015, 10, 240.	1.2	23
92	KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Molecular Oncology, 2015, 9, 1434-1446.	2.1	24
93	Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiation Oncology, 2015, 10, 21.	1.2	58
94	Definitive intensity modulated radiotherapy in locally advanced hypopharygeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure. Radiation Oncology, 2015, 10, 20.	1.2	8
95	Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience. Radiation Oncology, 2015, 10, 47.	1.2	22
96	Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. International Journal of Hyperthermia, 2015, 31, 609-614.	1.1	173
97	Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. International Journal of Biochemistry and Cell Biology, 2015, 62, 101-114.	1.2	23
98	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncology, The, 2015, 16, 1651-1658.	5.1	170
99	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. Journal of Clinical Oncology, 2015, 33, 4158-4166.	0.8	99
100	Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. European Urology Focus, 2015, 1, 173-184.	1.6	11
101	Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-associated Checkpoint Abrogation. Molecular Cancer Research, 2015, 13, 1544-1553.	1.5	9
102	Improved VMAT planning for head and neck tumors with an advanced optimization algorithm. Zeitschrift Fur Medizinische Physik, 2015, 25, 333-340.	0.6	5
103	Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10.. Journal of Clinical Oncology, 2015, 33, 5038-5038.	0.8	2
104	Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes and Cancer, 2015, 6, 317-327.	0.6	5
105	THABBR05: Quantification and Visualization of Treatment Plan Robustness in Radiotherapy. Medical Physics, 2015, 42, 3705-3705.	1.6	0
106	The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response Biological and Clinical Aspects. Cancers, 2014, 6, 1-27.	1.7	32
107	Prognostic value of matrix metalloproteinases in oral squamous cell carcinoma. Biotechnology and Biotechnological Equipment, 2014, 28, 1138-1149.	0.5	19
108	Forward treatment planning for modulated electron radiotherapy (MERT) employing Monte Carlo methods. Medical Physics, 2014, 41, 031712.	1.6	14

#	ARTICLE	IF	CITATIONS
109	Noninvasive referencing of intraocular tumors for external beam radiation therapy using optical coherence tomography: A proof of concept. Medical Physics, 2014, 41, 081704.	1.6	10
110	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. European Urology, 2014, 66, 799-802.	0.9	56
111	Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. FEBS Letters, 2014, 588, 653-658.	1.3	20
112	Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Radiation Oncology, 2014, 9, 122.	1.2	28
113	Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. , 2014, 143, 337-349.		16
114	Assessment of patient setup errors in IGRT in combination with a six degrees of freedom couch. Zeitschrift Fur Medizinische Physik, 2014, 24, 112-122.	0.6	29
115	Beamlet based direct aperture optimization for MERT using a photon MLC. Medical Physics, 2014, 41, 121711.	1.6	19
116	IMRT with 18FDG-PETCT based simultaneous integrated boost for treatment of nodal positive cervical cancer. Radiation Oncology, 2014, 9, 83.	1.2	38
117	CECOG expertsâ€™ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. Memo - Magazine of European Medical Oncology, 2013, 6, 75-82.	0.3	1
118	Physical examination during chemoradiation predicts outcome of locally advanced head and neck cancer. Secondary results of a randomized phase III trial (SAKK 10/94). Oral Oncology, 2013, 49, 1006-1009.	0.8	1
119	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. International Journal of Radiation Oncology Biology Physics, 2013, 87, 534-541.	0.4	23
120	Prostate Radiotherapy for Men with Metastatic Disease: A New Comparison in the STAMPEDE Trial. Clinical Oncology, 2013, 25, 318-320.	0.6	11
121	Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochemical and Biophysical Research Communications, 2013, 431, 264-269.	1.0	30
122	Macro Monte Carlo for dose calculation of proton beams. Physics in Medicine and Biology, 2013, 58, 2027-2044.	1.6	12
123	Prostate radiotherapy for men with metastatic disease: a new comparison in the <sc>S</sc>ystemic <sc>T</sc>herapy in <sc>A</sc>dvancing or <sc>M</sc>etastatic <sc>P</sc>rostate <sc>C</sc>ancer: <sc>E</sc>valuation of <sc>D</sc>rug <sc>E</sc>fficacy (<sc>STAMPEDE</sc>) trial. BJU International. 2013, 111, 697-699.	1.3	28
124	A Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign. Recent Results in Cancer Research, 2013, 194, 443-455.	1.8	1
125	The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants. Molecular Cancer Therapeutics, 2013, 12, 2415-2424.	1.9	27
126	Abstract C218: Relevance of p53 status for the response of tumor cells to MET inhibitors combined with irradiation.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
127	Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions. Prostate Cancer, 2012, 2012, 1-8.	0.4	6
128	Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: 10-Year Follow-Up of a Randomized Phase III Trial (SAKK 10/94). International Journal of Radiation Oncology Biology Physics, 2012, 82, 524-531.	0.4	34
129	High Dose-Rate Versus Low Dose-Rate Brachytherapy for Lip Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1205-1212.	0.4	41
130	Statistical Modeling of the Eye for Multimodal Treatment Planning for External Beam Radiation Therapy of Intraocular Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 84, e541-e547.	0.4	17
131	Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiotherapy and Oncology, 2012, 104, 213-218.	0.3	26
132	Compensability index for compensation radiotherapy after treatment interruptions. Radiation Oncology, 2012, 7, 208.	1.2	8
133	Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma. Radiation Oncology, 2012, 7, 175.	1.2	29
134	Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy. Radiation Oncology, 2012, 7, 132.	1.2	45
135	Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. Eur Urol 2012;61:443-451. European Urology, 2012, 61, e39.	0.9	4
136	MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. International Journal of Cancer, 2012, 130, 728-734.	2.3	49
137	Abstract 1786: Characterization of the inhibitory capacity of EMD1214063, a novel small molecule inhibitor of the MET hepatocyte growth factor receptor on a panel of MET mutated variants. , 2012, , .		0
138	Abstract 1909: Cytoprotective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. , 2012, , .		0
139	The Essential Role of Radiotherapy in the Treatment of Merkel Cell Carcinoma: A Study From the Rare Cancer Network. International Journal of Radiation Oncology Biology Physics, 2011, 81, e583-e591.	0.4	67
140	Urethral toxicity vs. cancer control—Lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Brachytherapy, 2011, 10, 286-294.	0.2	13
141	Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non-Small Cell Lung Cancer: A Phase I Trial. International Journal of Radiation Oncology Biology Physics, 2011, 80, 126-132.	0.4	46
142	In Response to Dr. Lacout et al.. International Journal of Radiation Oncology Biology Physics, 2011, 80, 962.	0.4	0
143	High-Dose (80 Gy) Intensity-Modulated Radiation Therapy with Daily Image-Guidance as Primary treatment for Localized Prostate Cancer. Strahlentherapie Und Onkologie, 2010, 186, 687-692.	1.0	21
144	Quantitative Analysis of Extracapsular Extension of Metastatic Lymph Nodes and its Significance in Radiotherapy Planning in Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1127-1132.	0.4	48

#	ARTICLE	IF	CITATIONS
145	Incidence of Small Lymph Node Metastases With Evidence of Extracapsular Extension: Clinical Implications in Patients With Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1366-1372.	0.4	24
146	Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center. <i>Radiation Oncology</i> , 2010, 5, 3.	1.2	9
147	Intensity-Modulated Radiotherapy for a Rendu-Osler-Weber Disease Patient with Recurrent Severe Epistaxis: A Case Report. <i>Case Reports in Medicine</i> , 2010, 2010, 1-4.	0.3	5
148	MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest. <i>Genes and Cancer</i> , 2010, 1, 1053-1062.	0.6	42
149	Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. <i>Cancer Letters</i> , 2010, 289, 228-236.	3.2	21
150	The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. <i>International Journal of Cancer</i> , 2009, 125, 741-745.	2.3	127
151	Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. <i>Brachytherapy</i> , 2009, 8, 45-51.	0.2	72
152	MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 809-815.	1.7	36
153	The Effectiveness and Safety of Proton Radiation Therapy for Indications of the Eye. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 211-221.	1.0	22
154	Prospective Study of Exclusive Strontium-90 β -Irradiation of Primary and Recurrent Pterygia with No Prior Surgical Excision. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 808-814.	1.0	12
155	Use of Gold Markers for Setup in Image-Guided Fractionated High-Dose-Rate Brachytherapy as a Monotherapy for Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 731-735.	1.0	12
156	Potential and future strategies for radiotherapy in hepatocellular carcinoma. <i>Liver International</i> , 2009, 29, 145-146.	1.9	6
157	Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2009, 91, 237-242.	0.3	22
158	Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. <i>Radiation Oncology</i> , 2008, 3, 22.	1.2	3
159	Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. <i>Radiation Oncology</i> , 2008, 3, 35.	1.2	27
160	Coupling of Mutated Met Variants to DNA Repair via Abl and Rad51. <i>Cancer Research</i> , 2008, 68, 5769-5777.	0.4	23
161	Matrix metalloproteinase-19 is a predictive marker for tumor invasiveness in patients with oropharyngeal squamous cell carcinoma. <i>International Journal of Biological Markers</i> , 2007, 22, 265-273.	0.7	5
162	Daily organ tracking in intensity-modulated radiotherapy of prostate cancer using an electronic portal imaging device with a dose saving acquisition mode. <i>Radiotherapy and Oncology</i> , 2006, 79, 101-108.	0.3	22

#	ARTICLE	IF	CITATIONS
163	Extracellular Signal-Regulated Kinase 1c (ERK1c), a Novel 42-Kilodalton ERK, Demonstrates Unique Modes of Regulation, Localization, and Function. <i>Molecular and Cellular Biology</i> , 2004, 24, 10000-10015.	1.1	58
164	The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. <i>Oncogene</i> , 2004, 23, 5387-5393.	2.6	170
165	Applicability and Dosimetric Impact of Ultrasound-Based Preplanning in High-Dose-Rate Brachytherapy of Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 351-357.	1.0	15
166	Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?. <i>Breast Cancer Research</i> , 2004, 6, R191-8.	2.2	106
167	Significant correlation of hypoxia-inducible factor-1 α with treatment outcome in cervical cancer treated with radical radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 494-501.	0.4	117
168	Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. <i>Oncogene</i> , 2003, 22, 8519-8523.	2.6	59
169	Palliative Interstitial HDR Brachytherapy for Recurrent Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 458-463.	1.0	28
170	Expression of transforming growth factor- β , epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. <i>Radiotherapy and Oncology</i> , 2002, 63, 275-283.	0.3	26
171	Human papillomavirus positive squamous cell carcinoma of the oropharynx. <i>Cancer</i> , 2001, 92, 805-813.	2.0	422
172	Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. <i>International Journal of Cancer</i> , 2001, 96, 41-54.	2.3	82
173	Altered Regulation of ERK1b by MEK1 and PTP-SL and Modified Elk1 Phosphorylation by ERK1b Are Caused by Abrogation of the Regulatory C-terminal Sequence of ERKs. <i>Journal of Biological Chemistry</i> , 2001, 276, 35280-35289.	1.6	45
174	Human papillomavirus positive squamous cell carcinoma of the oropharynx. , 2001, 92, 805.		2
175	Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 17-25.	0.4	48
176	Carcinoma of the Oropharynx: Local Failure as the Decisive Parameter for Distant Metastases and Survival. <i>Strahlentherapie Und Onkologie</i> , 2000, 176, 16-21.	1.0	14